

UNITED STATES OF AMERICA AMBASSADOR EDWARD T. McMULLEN VISITS CERBIOS-PHARMA SA

On September 7, Cerbios was honored by the visit of the US Ambassador to Switzerland and Liechtenstein, Edward McMullen Jr.

Aim of the visit of the Ambassador was to meet Cerbios' top management and shareholder in order to have a better view and understanding of Cerbios' ongoing and future activities in the USA.

Cerbios is active in the USA since 1982 with an established leadership with its reduced folates products used in oncology. In the past years, activities have strongly increased as service



Figure 1 From left to right: Gabriel Haering (CEO), Edward McMullen Jr. (US Ambassador), Anton van Troostenburg (Chairman), Rudolf Dudler (Chemholding Chairman), Sandor Galambos (US Embassy)

provider and CDMO (Contract Development and Manufacturing Operation) for originators needing Cerbios' expertise and know-how in handling and producing High Potency Active Ingredients (HPAIs) of the newest generation.

"Cerbios' forecasted growth in the coming years means an increased presence in the USA" confirms Gabriel Haering, Cerbios' CEO.

"Establishing an affiliate company through acquisition or a joint venture is an option we are considering in order to better serve our partners locally. The support of the US Embassy in Bern has really been remarkable till now".



Figure 2 Ambassador Edward McMullen Jr. visiting the R&D labs with Claudio Pozzoli (Chief Scientific Office)

“I was really positively surprised to discover not only Cerbios’ unique and innovative activities but also that a small canton like Ticino has an important Pharmaceutical Cluster heavily contributing to the canton’s GDP” says Ambassador McMullen.

“It is our goal to support Cerbios and other Swiss companies in strengthening their activities in the United States”.

For more information please contact:

Media contact : sales@cerbios.ch

About Cerbios-Pharma SA

Cerbios is a private company with its headquarters in Lugano, Switzerland, specialized in developing and producing active pharmaceutical ingredients (APIs), both chemical and biological, for its clients around the world. Cerbios is a world leader for some generic products used primarily to treat respiratory, dermatological and oncological diseases.

Cerbios also offers its clients an exclusive service to develop and produce highly active pharmaceutical ingredients (HAPIs) and biological monoclonal antibody tablets, recombinant proteins, conjugated monoclonal antibodies (ADCs) and probiotics for pharmaceutical use.

Cerbios is capable of offering a complete service to develop and register pharmaceutical products, tablets supplied for clinical research phases, the necessary regulatory documentation and subsequent marketing supplies. Cerbios products are marketed around the entire world, primarily in the USA, Japan and Europe.

Cerbios-Pharma SA

Via Figino 6
CH – 6527 Barbengo/Lugano (TI)
Switzerland

Phone : +41 (0) 91 985 63 11
Fax : +41 (0) 91 985 63 25